Status:
TERMINATED
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Thrombin Inhibition
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single o...
Eligibility Criteria
Inclusion
- Suitable veins for cannulation or repeated venipuncture
- Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and nor more than 100 kg
Exclusion
- History of any clinically significancy disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
- History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneurysms.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01150812
Start Date
June 1 2010
End Date
August 1 2010
Last Update
September 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Overland Park, Kansas, United States